Breathe Well Live Well
|
UK Body Rejects Novartis Asthma Drug Xolair In Kids Under 12
Wall Street Journal … on the publicly-funded National Health Service of Novartis AG's (NVS) asthma drug Xolair for treating severely asthmatic children under the age of 12, … |
View full post on asthma – Google News
|
Wall paints double kids' allergy risk
Times of India Chemicals found in wall paints and cleansers could practically double children's risk of developing asthma and hayfever. … |
View full post on asthma – Google News
|
Palatin Tech To Cut Work Force In Half, Do Reverse Stock Split
Wall Street Journal Palatin has been developing bremelanotide for male and female sexual dysfunction and PL-3994 for acute severe asthma. The company plans to submit plans for … Palatin Announces Strategic Realignment of Operations Palatin Reducing Workforce By 50%; To Effect 1-for-10 Reverse Stock Split … |
View full post on asthma – Google News
|
Suit Filed in Asthma Death
Wall Street Journal The family of a pregnant woman who died after suffering an asthma attack in a Brooklyn restaurant is suing the city claiming that medics on … Kin of Eutisha Rennix, who died of asthma in eatery, slaps city with lawsuit Family of Ignored Asthma Attack Woman to Sue City |
View full post on asthma – Google News
 MSN News UK |
UK's NICE Rejects Novartis' Xolair Again In Kids Aged 6 To 11
Wall Street Journal … or NICE, Thursday reiterated its earlier decision not to recommend Novartis AG's (NVS) asthma drug Xolair for children aged 6 to 11 years with severe, … Asthma rises as children return to school September marks child asthma peak Children with asthma 'at greater risk during September' |
View full post on asthma – Google News
 Stockopedia |
CORRECT: Vectura Licenses Patents To GlaxoSmithKline
Wall Street Journal VX) generics unit Sandoz handed back the US rights to VR315, a generic version of an asthma drug, to Vectura. Analysts said it signaled Sandoz wasn't sure … INTERVIEW: Vectura Patents For GSK's 573719 And 642444 Vectura and GlaxoSmithKline sign agreement over asthma patents Vectura boosted by deal with GSK worth over $30 million upfront plus royalties … |
View full post on asthma – Google News